| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Laboratories of Pharmacology, The Children's Cancer Research Foundation, and the Departments of Pathology and Medicine, Harvard Medical School, Boston, Massachusetts 02115
Characteristics of Methotrexate transport by normal and leukemic human leukocytes were measured in vitro. At high external drug levels (
20 µM) drug uptake by all cell types was temperature-insensitive, nonsaturable, and nonconcentrative. The steady-state cell/medium drug distribution ratio was about 0.03. During clinical treatment with Methotrexate, plasma drug levels generally reach 0.2 µM. At this lower drug level: (a) A temperature-sensitive and saturable mode of transport was demonstrable in all cell types except small lymphocytes. In normal granulocytes the steady-state drug distribution ratio reached 0.2. (b) Leukemic cell types showed a wide variation in capacity for uptake of the drug, and an association was seen between this capacity and clinical response to the drug.
1 Supported by Contracts PH 43-62-169 and PH 43-66-541 of the Cancer Chemotherapy National Service Center, and by Grant C 6516, all from the National Cancer Institute, NIH.
Received 6/28/67. Accepted 11/23/67.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |